Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

[The efficiency of complex recovery treatment of chronic obstructive pulmonary disease patients using subalin].

Lemko OI, Habor ML, Safronova LA, Lemko IS, Kopynets'.

Lik Sprava. 2012 Apr-Jun;(3-4):59-66. Ukrainian.

PMID:
23356139
3.

Effects of pharmacologic treatment based on airflow limitation and breathlessness on daily physical activity in patients with chronic obstructive pulmonary disease.

Minakata Y, Morishita Y, Ichikawa T, Akamatsu K, Hirano T, Nakanishi M, Matsunaga K, Ichinose M.

Int J Chron Obstruct Pulmon Dis. 2015 Jul 3;10:1275-82. doi: 10.2147/COPD.S84134. eCollection 2015.

4.

Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.

Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.

Clin Ther. 2012 Aug;34(8):1655-66.e5. doi: 10.1016/j.clinthera.2012.06.005. Epub 2012 Jul 11.

PMID:
22789766
5.

Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences.

Ohno T, Wada S, Hanada S, Sawaguchi H, Muraki M, Tohda Y.

Int J Chron Obstruct Pulmon Dis. 2014 Jan 21;9:107-14. doi: 10.2147/COPD.S56777. eCollection 2014.

6.

Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.

Wang C, Sun T, Huang Y, Humphries M, Bai L, Li L, Wang Q, Kho P, Firth R, D'Andrea P.

Int J Chron Obstruct Pulmon Dis. 2015 Jan 5;10:57-68. doi: 10.2147/COPD.S72650. eCollection 2015. Erratum in: Int J Chron Obstruct Pulmon Dis. 2015;10:1513.

7.

[Use of probiothic subalin for correction of endogenous intoxication syndrome in children with chronic hepatitis].

P'iankova OV, Zaĭtseva NIe, Safronova LA, Voronina SS, Osadcha AI, Malolitnia SV, Anoshyna MIu, Sten'kina SIe.

Lik Sprava. 2007 Apr-May;(3):84-91. Ukrainian.

PMID:
18271188
8.

Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD.

Chapman KR, Fogarty CM, Peckitt C, Lassen C, Jadayel D, Dederichs J, Dalvi M, Kramer B.

Int J Chron Obstruct Pulmon Dis. 2011;6:353-63. doi: 10.2147/COPD.S18529. Epub 2011 Jun 23.

9.

Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease.

Nishijima Y, Minami S, Yamamoto S, Ogata Y, Koba T, Futami S, Komuta K.

Int J Chron Obstruct Pulmon Dis. 2015 Feb 27;10:439-44. doi: 10.2147/COPD.S76836. eCollection 2015.

10.

Indacaterol therapy in moderate-to-severe chronic obstructive pulmonary disease: findings from a single-center primary care cohort.

Singh MP.

Int J Chron Obstruct Pulmon Dis. 2013;8:613-9. doi: 10.2147/COPD.S53707. Epub 2013 Dec 9.

11.

Effect of tiotropium on heart rate variability in stable chronic obstructive pulmonary disease patients.

Wu YK, Huang CY, Yang MC, Huang GL, Chen SY, Lan CC.

J Aerosol Med Pulm Drug Deliv. 2015 Apr;28(2):100-5. doi: 10.1089/jamp.2014.1125. Epub 2014 May 19.

PMID:
24840562
12.

Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.

Mahler DA, Waterman LA, Ward J, Gifford AH.

J Aerosol Med Pulm Drug Deliv. 2014 Apr;27(2):103-9. doi: 10.1089/jamp.2013.1038. Epub 2013 Jun 8.

PMID:
23745526
13.

Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.

Daley-Yates PT, Mehta R, Chan RH, Despa SX, Louey MD.

J Aerosol Med Pulm Drug Deliv. 2014 Aug;27(4):279-89. doi: 10.1089/jamp.2013.1040. Epub 2013 Sep 28.

PMID:
24074143
14.

The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD.

Papi A, Jones PW, Dalvi PS, McAulay K, McIver T, Dissanayake S.

Int J Chron Obstruct Pulmon Dis. 2015 Nov 9;10:2431-8. doi: 10.2147/COPD.S93375. eCollection 2015.

15.

Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.

Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.

Clin Ther. 2011 Dec;33(12):1974-84. doi: 10.1016/j.clinthera.2011.11.009.

PMID:
22177371
17.

Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.

Kerwin EM, Williams J.

Ther Adv Respir Dis. 2013 Feb;7(1):25-37. doi: 10.1177/1753465812470018. Epub 2013 Jan 7. Review.

PMID:
23296242
18.

Aerosol therapy and rehabilitation in chronic obstructive pulmonary disease (COPD).

Malik SK.

Indian J Chest Dis. 1968 Jul;10(3):142-8. No abstract available.

PMID:
16320511
19.

Oxidative stress and damage to erythrocytes in patients with chronic obstructive pulmonary disease--changes in ATPase and acetylcholinesterase activity.

Bukowska B, Sicińska P, Pająk A, Koceva-Chyla A, Pietras T, Pszczółkowska A, Górski P, Koter-Michalak M.

Biochem Cell Biol. 2015 Dec;93(6):574-80. doi: 10.1139/bcb-2015-0066. Epub 2015 Aug 18.

PMID:
26369587
20.

Lung function response to 12-week treatment with combined inhalation of long-acting beta2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease.

Kim WJ, Oh YM, Sung J, Kim TH, Huh JW, Jung H, Lee JH, Kim EK, Lee JH, Lee SM, Lee S, Lim SY, Shin TR, Yoon HI, Kwon SY, Lee SD.

Lung. 2008 Nov-Dec;186(6):381-6. doi: 10.1007/s00408-008-9103-9. Epub 2008 Aug 29.

PMID:
18758858

Supplemental Content

Support Center